Rhinovirus Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Rhinovirus Infections – Pipeline Review, H2 2016’, provides an overview of the Rhinovirus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhinovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rhinovirus Infections

The report reviews pipeline therapeutics for Rhinovirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rhinovirus Infections therapeutics and enlists all their major and minor projects

The report assesses Rhinovirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rhinovirus Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rhinovirus Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AIMM Therapeutics B.V.

AstraZeneca Plc

Aviragen Therapeutics, Inc.

Biological Mimetics, Inc.

Boehringer Ingelheim GmbH

Novartis AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Rhinovirus Infections Overview 6

Therapeutics Development 7

Pipeline Products for Rhinovirus Infections - Overview 7

Pipeline Products for Rhinovirus Infections - Comparative Analysis 8

Rhinovirus Infections - Therapeutics under Development by Companies 9

Rhinovirus Infections - Therapeutics under Investigation by Universities/Institutes 10

Rhinovirus Infections - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Rhinovirus Infections - Products under Development by Companies 13

Rhinovirus Infections - Products under Investigation by Universities/Institutes 14

Rhinovirus Infections - Companies Involved in Therapeutics Development 15

AIMM Therapeutics B.V. 15

AstraZeneca Plc 16

Aviragen Therapeutics, Inc. 17

Biological Mimetics, Inc. 18

Boehringer Ingelheim GmbH 19

Novartis AG 20

Rhinovirus Infections - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

BNT-014 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

KR-22809 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Monoclonal Antibodies to Inhibit Viral 3C Protease for Human Rhinovirus Infections - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Monoclonal Antibody for Human Rhinovirus Infections - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

OBR-5340 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

PL-402 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Polymer for Viral Infections - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Recombinant Peptide for Rhinovirus Infection - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Inhibit 3C Protease for Rhinovirus Infection - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

vapendavir - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Rhinovirus Infections - Dormant Projects 44

Rhinovirus Infections - Product Development Milestones 45

Featured News & Press Releases 45

Mar 03, 2015: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial 45

Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection 45

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for Rhinovirus Infections, H2 2016 7

Number of Products under Development for Rhinovirus Infections – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Rhinovirus Infections – Pipeline by AIMM Therapeutics B.V., H2 2016 15

Rhinovirus Infections – Pipeline by AstraZeneca Plc, H2 2016 16

Rhinovirus Infections – Pipeline by Aviragen Therapeutics, Inc., H2 2016 17

Rhinovirus Infections – Pipeline by Biological Mimetics, Inc., H2 2016 18

Rhinovirus Infections – Pipeline by Boehringer Ingelheim GmbH, H2 2016 19

Rhinovirus Infections – Pipeline by Novartis AG, H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Rhinovirus Infections – Dormant Projects, H2 2016 44

List of Figures

List of Figures

Number of Products under Development for Rhinovirus Infections, H2 2016 7

Number of Products under Development for Rhinovirus Infections – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Targets, H2 2016 22

Number of Products by Stage and Targets, H2 2016 22

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports